Antimetastatic potential of amide-linked local anesthetics: inhibition of lung adenocarcinoma cell migration and inflammatory Src signaling independent of sodium channel blockade by Piegeler, Tobias et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Antimetastatic potential of amide-linked local anesthetics: inhibition of lung
adenocarcinoma cell migration and inflammatory Src signaling independent
of sodium channel blockade
Piegeler, Tobias; Votta-Velis, E Gina; Liu, Guoquan; Place, Aaron T; Schwartz, David E;
Beck-Schimmer, Beatrice; Minshall, Richard D; Borgeat, Alain
Abstract: BACKGROUND: Retrospective analysis of patients undergoing cancer surgery suggests the
use of regional anesthesia may reduce cancer recurrence and improve survival. Amide-linked local anes-
thetics have antiinflammatory properties, although the mechanism of action in this regard is unclear.
As inflammatory processes involving Src tyrosine protein kinase and intercellular adhesion molecule-1
are important in tumor growth and metastasis, we hypothesized that amide-linked local anesthetics may
inhibit inflammatory Src-signaling involved in migration of adenocarcinoma cells. METHODS: NCI-
H838 lung cancer cells were incubated with tumor necrosis factor-￿ in absence/presence of ropivacaine,
lidocaine, or chloroprocaine (1 nM-100 ￿M). Cell migration and total cell lysate Src-activation and inter-
cellular adhesion molecule-1 phosphorylation were assessed. The role of voltage-gated sodium-channels
in the mechanism of local anesthetic effects was also evaluated. RESULTS: Ropivacaine treatment (100
￿M) of H838 cells for 20 min decreased basal Src activity by 62% (P=0.003), and both ropivacaine and
lidocaine coadministered with tumor necrosis factor-￿ statistically significantly decreased Src-activation
and intercellular adhesion molecule-1 phosphorylation, whereas chloroprocaine had no such effect. Mi-
gration of these cells at 4 h was inhibited by 26% (P=0.005) in presence of 1 ￿M ropivacaine and 21% by
1 ￿M lidocaine (P=0.004). These effects of ropivacaine and lidocaine were independent of voltage-gated
sodium-channel inhibition. CONCLUSIONS: This study indicates that amide-, but not ester-linked, local
anesthetics may provide beneficial antimetastatic effects. The observed inhibition of NCI-H838 cell mi-
gration by lidocaine and ropivacaine was associated with the inhibition of tumor necrosis factor-￿-induced
Src-activation and intercellular adhesion molecule-1 phosphorylation, providing the first evidence of a
molecular mechanism that appears to be independent of their known role as sodium-channel blockers.
DOI: 10.1097/ALN.0b013e3182661977
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-66741
Originally published at:
Piegeler, Tobias; Votta-Velis, E Gina; Liu, Guoquan; Place, Aaron T; Schwartz, David E; Beck-Schimmer,
Beatrice; Minshall, Richard D; Borgeat, Alain (2012). Antimetastatic potential of amide-linked local
anesthetics: inhibition of lung adenocarcinoma cell migration and inflammatory Src signaling independent
of sodium channel blockade. Anesthesiology, 117(3):548-59. DOI: 10.1097/ALN.0b013e3182661977
1 
Anti-metastatic Potential of Amide-linked Local Anesthetics: 
Inhibition of Lung Adenocarcinoma Cell Migration and Inflammatory 
Src Signaling Independent of Sodium Channel Blockade 
 
 
Tobias Piegeler*, M.D., Resident/Post-doctoral Research Fellow1,5 
E. Gina Votta-Velis*, M.D., Ph.D., Associate Professor1,4 
Guoquan Liu, Ph.D., Research Assistant Professor2 
Aaron T. Place, Ph.D., Post-doctoral Research Fellow2 
David E. Schwartz, M.D., Professor of Anesthesiology1 
Beatrice Beck-Schimmer, M.D., Professor of Anesthesiology1,5 
Richard D. Minshall, Ph.D., Associate Professor1,2,3 
Alain Borgeat, M.D., Professor of Anesthesiology1,6 
 
Departments of Anesthesiology1 & Pharmacology2, Center for Lung and Vascular 
Biology3, University of Illinois at Chicago, and Jesse Brown VA Medical Center4, 
Chicago IL, USA 
5Institute of Anesthesiology, University Hospital Zurich, Switzerland 
6Division of Anesthesiology, Balgrist University Hospital Zurich, Switzerland 
* Denotes equal contribution 
Support was provided from institutional sources, NIH HL60678 and HL71626 (RDM), the Lung 
Zurich, Switzerland, and the Swiss Society of Anesthesiology and Resuscitation, Bern, 
Switzerland (both BBS). 
Address for Correspondence: 
Alain Borgeat, MD 
Professor of Anesthesiology 
Division of Anesthesiology  
Balgrist University Hospital  
Forchstrasse 340 
CH-8008 Zurich 
Switzerland 
Tel. +41 41 44 386 38 32  
Fax +41 44 386 11 09 
Email: alain.borgeat@balgrist.ch 
Running title: Anti-metastatic potential of ropivacaine 
Summary statement: Amide, but not ester local anesthetics reduced Src and ICAM-1 
phosphorylation independently of their activity on sodium channels or toxic effects on the lung 
cancer cell line. 
 
*Manuscript (Title Page, Abstract, Body, References)
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
2 
Abstract 
Background: Retrospective analysis of patients undergoing cancer surgery suggests the 
use of regional anesthesia may reduce cancer recurrence and improve survival. Amide-
linked local anesthetics have anti-inflammatory properties, although the mechanism of 
action in this regard is unclear. As inflammatory processes involving Src tyrosine protein 
kinase (Src) and intercellular adhesion molecule-1 (ICAM-1) are important in tumor 
growth and metastasis, we hypothesized that amide-linked local anesthetics may inhibit 
inflammatory Src-signaling involved in migration of adenocarcinoma cells. 
Methods: NCI-H838 lung cancer cells were incubated with Tumor Necrosis Factor- 
(TNF-) in absence/presence of ropivacaine, lidocaine, or chloroprocaine (1nM-100M). 
Cell migration and total cell lysate Src-activation and ICAM-1-phosphorylation were 
assessed. The role of voltage-gated sodium-channels in the mechanism of local 
anesthetic effects was also evaluated. 
Results: Ropivacaine treatment (100M) of H838 cells for 20 minutes decreased basal 
Src activity by 62% (p=0.003), and both ropivacaine and lidocaine co-administered with 
TNF- statistically significantly decreased Src-activation and ICAM-1-phosphorylation, 
whereas chloroprocaine had no such effect. Migration of these cells at 4 hours was 
inhibited by 26% (p=0.005) in presence of 1M ropivacaine and 21% by 1M lidocaine 
(p=0.004). These effects of ropivacaine and lidocaine were independent of voltage-
gated sodium-channel inhibition. 
Conclusions: This study indicates that amide-, but not ester-linked local anesthetics may 
provide beneficial anti-metastatic effects. The observed inhibition of NCI-H838 cell 
migration by lidocaine and ropivacaine was associated with the inhibition of TNF-
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induced Src-activation and ICAM-1 phosphorylation, providing the first evidence of a 
molecular mechanism which appears to be independent of their known role as sodium-
channel blockers. 
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Introduction 
Lung cancer is the leading cause of death from cancer in males and the second 
leading cause of death in females1; effective treatment remains a challenge. Even if 
patients undergo complete tumor resection including lymphadenectomy, there is still a 
high rate of relapse due to undetected micrometastasis2-4. Regional anesthesia with 
local anesthetics in combination with general anesthesia is commonly used in patients 
undergoing tumor resection of the lung5.  
It is well known that amide-linked local anesthetics – as opposed to the ester-
linked compounds – can exert inhibitory effects on inflammatory processes6, e.g., as 
ropivacaine has been shown to possess anti-inflammatory properties in a model of 
pulmonary inflammation7. Also, the systemic use of lidocaine in patients undergoing 
colo-rectal surgery led to a decrease in inflammatory cytokine release as well as a 
shortened hospital stay8.  
There is increasing evidence that inflammatory mechanisms may play an 
important role in the development and growth of cancer metastasis9. Cytokines such as 
Tumor Necrosis Factor- (TNF-) increase the expression of Intercellular Adhesion 
Molecule-1 (ICAM-1), a cell surface receptor required for leukocyte adhesion10 and 
tumor invasion11, in the H838 non-small cell lung cancer cell line12. ICAM-1 also 
facilitates tumor cell extravasation via the binding of neutrophils13. TNF- is known to 
induce activation of Src protein tyrosine kinase, which functions as a regulator of 
endothelial permeability14. Src mediated phosphorylation of ICAM-1 is necessary for 
neutrophil adhesion to the endothelium during acute lung inflammation and injury15, a 
process considered to induce vascular hyperpermeability10. Additionally, Src is involved 
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in signaling epithelial-to-mesenchymal transformation and extravasation of cancer 
cells16,17, processes that are necessary for solid tumor metastasis18.  
Recently published retrospective analysis of patients undergoing cancer surgery 
showed a possible benefit of the perioperative use of regional anesthesia.  Long-term 
survival after colon cancer surgery19 and cancer recurrence after radical prostatectomy 
for prostate cancer20 or breast cancer21 were significantly improved by epidural 
anesthesia/analgesia compared to patient-controlled analgesia (PCA) with opioids. The 
mechanism by which regional anesthesia might prove to be beneficial at the molecular 
level in this context is not yet known. We hypothesized that this effect might be related 
to the anti-inflammatory properties of local anesthetics.  
The primary goal of this study was to determine whether amide-linked local 
anesthetics (ropivacaine and lidocaine) attenuate TNF-induced Src activation and 
ICAM-1 phosphorylation in H838 human lung cancer cells and whether these effects are 
due to the inhibition of voltage-gated sodium channels. Secondly, we examined whether 
lidocaine, ropivacaine, or chloroprocaine inhibit migration of this cancer cell line in vitro. 
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Materials and Methods 
Cell culture 
The human NCI-H838 lung cancer cell line (CRL-5844, ATCC, Rockville, MD, 
USA), isolated from an 80-year old patient with stage 3B non-small cell lung cancer, 
was cultured in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented 
with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin and 1% L-glutamine (all 
from Gibco Invitrogen, Carlsbad, CA, USA). Experiments were performed with 70 – 
100% confluent cells from passages 49 – 55. Prior to the experiments, cells were grown 
in reduced-serum (RPMI+1% FBS) for 16 hours.  All cells were maintained in 5% CO2 - 
95% room air in a water-jacketed 37°C incubator. 
 
Experimental procedure 
Cell monolayers were incubated either with Escherichia coli serotype 055:B5 
lipopolysaccharide (Sigma-Aldrich, St. Louis, MO, USA) at a concentration of 4 μg/ml 
diluted in RPMI+1% FBS medium for 4 hours, or with TNF- (Gibco Invitrogen, 
Carlsbad, CA, USA) at a concentration of 20 ng/ml, also diluted in RPMI-1% FBS, for 20 
minutes for Western Blot or 4 hours for assessment of cell migration and cytotoxic 
effects. 
Ropivacaine 0.5 % (Naropin®, APP Pharmaceuticals, Schaumburg, IL, USA), Lidocaine 
2% (APP Pharmaceuticals, Schaumburg, IL, USA) or Chloroprocaine 3% (Bedford 
Laboratories, Bedford, OH, USA) were diluted with RPMI+1% FBS medium to achieve 
the concentrations tested (1 nM – 100 μM) for the treatment of H838 cells in presence 
or absence of TNF- or lipopolysaccharide. For some experiments, cells were 
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7 
pretreated with the voltage-gated sodium channel (VGSC) agonist veratridine (Sigma, 
St. Louis, MO, USA) for 30 minutes or with the VGSC antagonist tetrodotoxin (Sigma, 
St. Louis, MO, USA) for 10 minutes.  
 
Cytotoxicity Assay 
 Cytotoxicity was measured using the Cytotoxicity Detection KitPlus (Roche, 
Indianapolis, IN, USA) following the instructions by the manufacturer. The assay 
measures the activity of lactate dehydrogenase as a marker for cytotoxicity in cell 
culture supernatants. NCI-H838 cells were incubated for 4 hours in low serum RPMI-
1640 medium (1 % FBS, 1 % penicillin/streptomycin, 1 % L-glutamine) with different 
concentrations of ropivacaine, lidocaine or chloroprocaine (1 nM – 100 M) in presence 
or absence of TNF- at a concentration of 20 ng/ml. 30 minutes prior to the end of the 
experiment, some cells were lysed by the addition of 10% Triton-X 100 (Sigma, St. 
Louis, MO, USA) to measure the maximal release of lactate dehydrogenase. Then the 
supernatant was collected and centrifuged for 5 minutes at 700 g to remove all cellular 
debris. Lactate dehydrogenase content was determined by the measurement of red 
formazan, derived from the yellow tetrazolium salt INT (2-(4-Iodophenyl)-3-(4-
nitrophenyl)-5-phenyl-2H-tetrazolium chloride) by a catalyst after reduction of NAD+ to 
NADH+H+ by lactate dehydrogenase. Cytotoxicity was then calculated according to the 
following formula: 
Cytotoxicity % = (experimental release – background)/(maximum release-background) x 
100. 
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Cell harvest and lysis 
After the end of the experiment, cells were washed once with ice-cold Dulbecco’s 
phosphate buffered saline (PBS, Cellgro, Manassas, VA, USA) and lysed with 
radioimmunoprecipitation (RIPA) buffer (Boston Bioproducts, Ashland, MA, USA) 
supplemented with protease inhibitor cocktail (PIC), 200 mM 
phenylmethylsulfonylfluoride (PMSF), 1 mM ethylendiaminetetraacetate (EDTA), 1 mM 
sodium-fluoride (NaF) and 1 mM sodium-orthovanadate (Na3VO4, all from Sigma, St. 
Louis, MO, USA). After a brief sonification and 10 minute centrifugation at 4°C and 
13,200 rpm in an Eppendorf 5415R microcentrifuge (Eppendorf AG, Hamburg, 
Germany), the supernatant was collected and stored at -20°C until further use. Total 
protein concentration was determined using a BCA protein assay kit (Pierce Thermo 
Fisher Scientific, Rockford, IL, USA) according to the manufacturer’s instructions using 
albumin to generate a standard curve. 
 
Western Blot 
Before boiling the lysates for 5 minutes, 6x Laemmli sample buffer (Boston 
Bioproducts, Ashland, MA, USA) was added at a final concentration of 1x as well as 30 
mM Dithiothreitol (DTT, Biorad, Hercules, CA, USA). Equal amounts of protein (10 μg) 
were loaded in each lane of a 10% polyacrylamide gel for Sodium Dodecyl Sulfate Poly-
Acrylamide Gel Electrophoresis (SDS-PAGE). After SDS-PAGE, the proteins were 
transferred to a nitrocellulose membrane (Biorad, Hercules, CA, USA) and blocked with 
5% blotting grade non-fat dry milk (Biorad, Hercules, CA, USA) dissolved in Tris 
buffered saline (TBS) with 0.05% TWEEN-20 (Sigma, St. Louis, MO, USA) (TBST) for 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
9 
30 minutes. The membranes were then probed with primary antibodies in TBST for 2 
hours on a shaker at room temperature or at 4°C overnight. Three washes with TBST 
were followed by incubation of the membrane with horseradish-peroxidase (HRP)-
conjugated secondary antibody (KPL, Gaithersburg, MD, USA) in 5% milk in TBST for 1 
hour on a shaker at room temperature. After four washes with TBST, enhanced 
chemiluminescence (ECL) solution (Thermo Scientific, Rockford, IL, USA) was used to 
visualize the bands on HyBlot CL film (Denville, South Plainfield, NJ, USA). To detect 
the total amount of ICAM-1 or Src on the same membranes after detection of the 
phosphorylated forms of the proteins, the antibodies were removed from the 
membranes using Restore Western Blot Stripping buffer (Thermo Scientific, Rockford, 
IL, USA).  Subsequently, the membranes were blocked and re-probed with primary and 
secondary antibodies as stated above. 
Primary antibodies for pY419 Src and (total) Src were purchased from Cell 
Signaling Technologies (Danvers, MA, USA) and for pY512 ICAM-1 and (total) ICAM-1 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
 
Cell migration assay 
NCI-H838 lung cancer cells were suspended at a concentration of 106/ml and 
were stained with fluorescent dye (Cytoselect®, Cell Biolabs, San Diego, CA, USA). 
Then, 105 NCI-H838 cells were resuspended in 300 μl RPMI-1640 medium with 0% 
FBS and no other supplements or with different concentrations of ropivacaine, lidocaine 
or chloroprocaine (1 pM – 100 μM) and were incubated for 15 minutes at room 
temperature and placed into the upper chamber of a 6.5 mm Transwell® polycarbonate 
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10 
membrane insert with 8 μm pores (Corning Life Sciences, Lowell, MA, USA). The 
inserts were then placed into 500 μl complete medium (RPMI-1640, 10 % FBS, 1 % 
penicillin/streptomycin, 1 % L-glutamine plus the same concentration of local anesthetic 
as present in the upper chamber) in a 24-well plate. To assess the reversibility of the 
inhibition of cell migration, cells were washed three times after incubation with 
ropivacaine before resuspending in 300 μl RPMI-1640 medium and placement into the 
upper chamber of a Transwell® insert. After 4 hours, all inserts were removed from the 
well. The remaining fluid in the upper chamber was removed and the inserts were 
placed into fresh wells filled with cell detachment and lysis solution. A Wallac Victor2® 
microplate reader (Perkin Elmer, Waltham, MA, USA) was used to detect fluorescence 
at 485/535 nm (Excitation/Emission). 
 
Statistical analysis 
Normal distribution of all data was first assessed with a Shapiro-Wilk test. 
Normally distributed data (cytotoxicity) are presented as column scatter plots with the 
mean of each group indicated by a horizontal line.  These results were analyzed using 
three-way ANOVA with the local anesthetics, their concentration, and the presence or 
absence of TNF- as factors to be tested. All other data (densitometry, migration), also 
presented as column scatter plots with a horizontal line indicating the mean, were 
analyzed using non-parametric testing methods (Kruskal-Wallis and Mann-Whitney U-
test). In order to maintain the family wise error rate below 0.05, the result of multiple 
comparisons (Mann-Whitney U-tests) following a statistically significant Kruskal-Wallis 
test were evaluated for significance by the Simes-Hochberg method.  All tests were 
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11 
performed in a non-blinded and two-tailed manner with the SPSS Statistics Software 
Version 19 (IBM, Zurich, Switzerland). Graphs were generated using GraphPad Prism 
for Mac, Version 5 (GraphPad Software, La Jolla, CA, USA). All experiments were 
performed at least three times. A p-value of <0.05 was considered statistically 
significant. 
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Results 
Effect of ropivacaine, lidocaine and chloroprocaine on cytotoxicity 
 First the cytotoxic effect of different local anesthetics was evaluated by 
measuring the activity of lactate dehydrogenase in cell culture supernatants after 
incubation of NCI-H838 lung cancer cells with different concentrations (1 nM, 1 M, 10 
M, 100 M) of ropivacaine, lidocaine, and chloroprocaine in the absence or presence 
of Tumor Necrosis Factor- (TNF-) at a concentration of 20 ng/ml for 4 hours. 
Untreated cells served as control. Baseline cytotoxicity in untreated cells was found to 
be 13% and treatment with TNF-α alone lead to an increase in cytotoxicity of 99% 
compared to control (Supplemental digital content 1, A-C). The overall data analysis 
was conducted using three-way ANOVA. Cytotoxicity was the dependent factor and the 
type of local anesthetic, its concentration, and presence or absence of TNF- the 
factors to be investigated. The analysis revealed that only the presence of TNF- 
significantly increased cytotoxicity (p=<0.001). Neither the application of the different 
local anesthetics (p=0.264), nor their different concentrations (p=0.919) had any 
influence on cytotoxicity measures. An analysis of the interaction of the local 
anesthetics with their different concentrations (p=0.908) or with TNF- (p=0.358) did not 
reach statistical significance. The same result could be observed for the combined 
analysis of TNF- together with the different concentrations of the local anesthetics 
(p=0.979) or a combination of all three factors (p=0.992).  
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Effect of ropivacaine on the phosphorylation status of Src and ICAM-1 in NCI-H838 
lung cancer cells 
NCI-838 lung cancer cells were first incubated for 20 minutes with TNF- at a 
concentration of 20 ng/ml in the presence or absence of different concentrations of 
ropivacaine (1 nm, 1 μM, 10 μM, 100 μM). Whole cell lysates were analyzed by Western 
blot analysis, probing for Src, phosphorylated at tyrosine 419 (pY419 Src) and total Src 
(Figure 1A). 
The phosphorylation of Src at tyrosine 419 (pY419 Src) increased by 44 % upon 
stimulation with TNF- compared to control (Mann-Whitney U-test, p=0.001, 
Supplemental digital content 2).  Incubation of cells with ropivacaine alone for 20 
minutes led to a significant decrease in phosphorylation of Src compared to untreated 
cells (=control) of 62 % by 100 M (p=0.003, Figure 1B). Ten M ropivacaine led to a 
48 % decrease, which was not considered statiscally significant (p=0.022, Figure 1B). 
Co-incubation of TNF- with different concentrations of ropivacaine showed that 
ropivacaine also decreased the phosphorylation of Src at tyrosine 419 in a significant 
manner compared to TNF- alone even at 1 M by 52% (p=0.022, Figure 1C). Higher 
concentrations of ropivacaine led to an even greater attenuation of TNF--induced Src 
phosphorylation (58 % by 10 M, p=0.006 and 60 % by 100 M, p=0.017, Figure 1C).  
The same whole cell lysates were also analyzed via Western blot probing for 
ICAM-1, phosphorylated at tyrosine 512 (pY512 ICAM-1) and total ICAM-1 (Figure 2A).  
Compared to untreated cells, TNF-α increased the phosphorylation of ICAM-1 at 
tyrosine 512 (pY512 ICAM-1) by 53 % (Mann-Whitney U-test, p=0.001, Supplemental 
digital content 2).  Increasing concentrations of ropivacaine did not alter the 
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phosphorylation status of ICAM-1 (Kruskal-Wallis test, p=0.99, Figure 2B), but co-
incubation with ropivacaine resulted in a significant attenuation of TNF--induced 
phosphorylation of ICAM-1 at tyrosine 512 compared to treatment with TNF- alone, 
with significant inhibition beginning at 10 M (40 % decrease, p=0.01, Figure 2C). A 
higher dose of ropivacaine further decreased TNF--induced ICAM-1 phosphorylation 
(71 % by 100 M, p<0.001, Figure 2C). A 32 % decrease by 1 M was also observed 
but not considered statistically significant (p=0.031, Figure 2C). 
 
Effect of lidocaine on the phosphorylation status of Src and ICAM-1 in NCI-H838 lung 
cancer cells 
To evaluate the effect of lidocaine on NCI-H838 lung cancer cell Src signaling, 
cells were treated with increasing concentrations of lidocaine (1 nm, 1 μM, 10 μM, 100 
μM) for 20 min and again analyzed for Src phosphorylation via Western blot (Figure 
3A). Although a dose-dependent decrease in Src phosphorylation at tyrosine 419 was 
observed after incubation of the cells with lidocaine for 20 minutes, this decrease did not 
reach statistical significance (Kruskal-Wallis test, p=0.146, Figure 3B). However, a 
significant decrease in TNF--induced Src phosphorylation of 73 % was observed after 
co-incubation of cells with TNF- and 10 M (p=0.012) of lidocaine (Figure 3C). ICAM-
1 phosphorylation in the Western blot (Figure 4A) was not affected by lidocaine alone 
(Kruskal-Wallis test, p=0.624, Figure 4B), but when co-incubated with TNF-, lidocaine 
reduced ICAM-1 phosphorylation compared to TNF- alone in a significant manner (73 
% decrease by 100 M, p=0.002, Figure 4C). An attenuation of 50 % was observed 
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after co-incubation of 1 M lidocaine with TNF-, but did not reach statistical 
significance (p=0.022, Figure 4C). 
 
 
Effect of chloroprocaine on the phosphorylation status of Src and ICAM-1 in NCI-H838 
lung cancer cells  
To compare the results observed with the amide-linked local anesthetics 
(ropivacaine, lidocaine) to an ester-linked local anesthetic, NCI-H838 lung cancer cells 
were treated as above with increasing concentrations of the ester-linked chloroprocaine 
(1 nm, 1 M, 10 M, 100 M). Analysis of Src phosphorylation (Figure 5A) in H838 cell 
lysates showed that chloroprocaine had no effect on Src activation, either alone 
(Kruskal-Wallis test, p=0.305, Figure 5B) or when co-incubated with TNF- compared 
to TNF- alone (p=0.443, Figure 5C). There was also no effect of chloroprocaine on 
ICAM-1 phosphorylation (Figure 6A) after incubation with chloroprocaine alone 
compared to control (Figure 6B, Kruskal-Wallis test, p=0.924), and after co-incubation 
with TNF- (Figure 6C, p=0.217). 
 
Effect of ropivacaine on the phosphorylation status of Src and ICAM-1 in NCI-H838 
lung cancer cells after 4 hours lipopolysaccharide treatment 
In additional experiments, NCI-H838 cells were incubated with bacterial 
lipopolysaccharide at a concentration of 4 g/ml with or without different concentrations 
of ropivacaine (1 nm, 1 M, 10 M, 100 M) for 4 hours. Subsequently, whole cell 
lysates were analyzed using the Western Blot technique, again blotting for the 
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phosphorylated forms of Src (pY419 Src, Supplemental digital content 3) and ICAM-1 
(pY512 ICAM-1, Supplemental digital content 4) as well as the total amount of both 
proteins. Compared to untreated cells, incubation with lipopolysaccharide led to a 46 % 
increase in Src phosphorylation (Mann-Whitney U-test, p=0.001, Supplemental digital 
content 2), whereas 1 M and 10 M of ropivacaine significantly decreased Src 
phosphorylation by 60% (p=0.006) and 57 % (p=0.016, Supplemental digital content 
3B), respectively. When co-incubated with lipopolysaccharide, increasing 
concentrations of ropivacaine attenuated Src phosphorylation by 52 % (100 M, 
p=0.001, Supplemental digital content 3C). 
Densitometry analysis revealed an increase in ICAM-1 phosphorylation by 
lipopolysaccharide of 58% compared to control (Mann-Whitney U-test, p=0.001, 
Supplemental digital content 2), but treatment with increasing ropivacaine 
concentrations alone did not change the phosphorylation status of the protein (Kruskal-
Wallis test, p=0.98, Supplemental digital content 4B). In contrast, co-incubation of 
lipopolysaccharide with ropivacaine decreased lipopolysaccharide-induced 
phosphorylation of ICAM-1 at tyrosine 512 after 4 hours of stimulation, with the lowest 
effective dose of 10 M decreasing ICAM-1 phosphorylation by 45% (p=0.004, 
Supplemental digital content 4C).  
 
Effect of sodium channel activator veratridine and sodium-channel blocker 
tetrodotoxin on phosphorylation status Src and ICAM-1 in NCI-H838 lung cancer cells 
 To investigate whether the voltage-gated sodium channel plays a role in 
activation of Src and subsequent phosphorylation of ICAM-1, NCI-H838 lung cancer 
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cells were treated with the alkaloid and voltage-gated sodium channel (VGSC) agonist 
veratridine at a concentration of 0.015 mM for 45 minutes before the cells were 
harvested, lysed and prepared for Western Blot analysis of pY419 Src and pY512 
ICAM-1 as well as the total amounts of each protein (Figure 7A i and ii). This 
concentration was chosen, since it was shown that 7.4 M veratridine abolishes 
lidocaine-induced membrane depolarization of intestinal cells22. For our experiments, 
we doubled this concentration. Densitometry analysis revealed that neither Src 
activation nor ICAM-1 phosphorylation was affected by treatment with veratridine 
compared to control (Kruskal-Wallis test, p=0.98, Figure 7A iii).  
 The effect of tetrodotoxin, a non-local anesthetic VGSC antagonist, was 
investigated. Tetrodotoxin at a concentration of 100 nM (10-7 M) was used, as this 
concentration is known to inhibit all VGSCs in excitable membranes23.  NCI-H838 lung 
cancer cells were pre-treated with tetrodotoxin for 10 minutes before TNF- (20 ng/ml) 
was added. Cells were lysed after 20 minutes. Representative Western blots of 
phosphorylated Src and ICAM-1 as well as the total amount of the proteins are shown in 
Figure 7B i and ii. Densitometry analysis revealed no difference in Src and ICAM-1 
phosphorylation after pre-treatment with tetrodotoxin and subsequent addition of TNF- 
compared to TNF- alone (Mann-Whitney U-test, p=0.48 for Src and p=0.827 for ICAM-
1, Figure 7B iii and B iv). 
 
Migratory ability of NCI-H838 lung cancer cells in the presence of ropivacaine, lidocaine 
and chloroprocaine 
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 NCI-H838 cells, stained with a fluorescent dye, were allowed to migrate through 
an 8 μm pore polycarbonate membrane for 4 hours in the presence or absence of 
different concentrations of ropivacaine, lidocaine or chloroprocaine (1 pM, 1nM, 1 M, 
10 M, 100 M). Migrated cells were detached from the bottom of the membrane, and 
lysed. Fluorescence was measured at 485/535 nm (excitation/emission) (Figure 8). 
Compared to untreated cells (=control), ropivacaine induced a significant 
decrease in fluorescence – and therefore the number of cells migrated – by 26% 
(p=0.005) at 1 M concentration. A higher concentrations decreased fluorescence by 
28% (10 M, p=0.003, Figure 8A). This effect was completely abolished by removal of 
ropivacaine after the initial 15 minutes of incubation (Kruskal-Wallis test, p=0.447, 
Figure 8D). 
Treatment with lidocaine decreased fluorescence after 4 hours of migration 
(Kruskal-Wallis test, p=0.004). 1 M of lidocaine attenuated migration by 21% compared 
to control (p=0.004), whereas 10 M and 100 M led to a decrease of 23% (p=0.002) 
and 20% (p=0.009), respectively (Figure 8B). In contrast, incubation with different 
concentrations of chloroprocaine had no effect on fluorescence measured after 4 hours 
(Kruskal-Wallis test, p=0.718, Figure 8C).  
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Discussion 
 The results of this study indicate that the amide-linked local anesthetics 
ropivacaine and lidocaine inhibit Src (auto)phosphorylation at tyrosine 419 induced by 
inflammatory stimuli such as TNF-, and that ropivacaine inhibited Src phosphorylation 
(activity) even in the absence of inflammatory stimuli. In contrast, the ester-linked local 
anesthetic chloroprocaine had no such effect. In addition, we observed decreased Src-
mediated phosphorylation of ICAM-1 at tyrosine 512 in presence of ropivacaine and 
lidocaine in NCI-H838 lung cancer cells treated with TNF-and lipopolysaccharide). 
Moreover, ropivacaine and lidocaine were shown to inhibit the migration of H838 cancer 
cells. 
Interestingly, the inhibitory effect on either the phosphorylation of Src and ICAM-1 
or migration of lung cancer cells was observed with amide local anesthetics 
(ropivacaine and lidocaine), but not with ester local anesthetics (Chloroprocaine). 
Previous studies also demonstrated a selective protective effect of amide local 
anesthetics as compared to the ester-linked compounds. De Klaver et al demonstrated 
that lidocaine, ropivacaine and bupivacaine protected endothelial cells against 
lipopolysaccharide -induced cellular injury, whereas procaine and tetracaine did not24.  
Recently, Src tyrosine protein kinase has become a key research focus of cancer 
development, growth and metastasis. Src is involved in signaling epithelial-to-
mesenchymal transformation, e. g. via loss of E-cadherin and subsequently decreased 
cell-cell-adhesion16,17,25 necessary for solid tumor metastasis18. Src is activated either 
by (auto)phosphorylation at tyrosine 419 and/or by dephosphorylation at tyrosine 52926. 
This study showed that ropivacaine dose-dependently decreased Src activation in NCI-
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H838 lung cancer cells, even in the absence of an inflammatory stimulus (TNF- or 
lipopolysaccharide), although stimulation was necessary to observe an effect of 
ropivacaine on Src-dependent ICAM-1 phosphorylation at tyrosine 512. This indicates 
that Src might be the primary target of ropivacaine and that phosphorylation of ICAM-1 
is attenuated secondary to the inhibition of Src activity, as ICAM-1 was previously 
shown to be a Src substrate15.  
Local anesthetics are known to block the voltage-gated sodium channel 
(VGSC)27. The inhibitory effect of ropivacaine and lidocaine on Src activation and ICAM-
1 phosphorylation, as observed in this study, is independent from the inhibition of the 
VGSC. No change in the phosphorylation status of the two proteins after incubation with 
the sodium channel agonist veratridine was observed. Neither Src nor ICAM-1 
phosphorylation induced by TNF- was altered by pretreatment with the sodium 
channel inhibitor tetrodotoxin. These results are in accordance with those of another 
study that demonstrated VGSC-independent inhibition of TNF--induced epithelial 
chemokine secretion28. However, there is some evidence that VGSCs linked with Fyn, 
another member of the Src protein tyrosine kinase family, might play a role in the 
migration of neuronal cells and metastasis29. Also, an inhibition of VGSCs in other 
human non-small-cell lung cancer cell lines led to a reduction of in vitro invasion of 
these malignant cells30. 
The identification of Src as a key enzyme in tumor growth and metastasis has led 
to the development of several “targeted therapies”, such as Src-inhibitors or combined 
Bcr/Abl and Src-inhibitors (e. g. Dasatinib®, Bristol-Myers Squibb, New York, NY, 
USA)31. Most of these compounds act as ATP-competitive inhibitors at the ATP-binding 
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pocket of Src32. It would therefore be interesting to determine in future studies how 
ropivacaine inhibits Src activity, assessing for example whether it competes with ATP 
for binding within the Src kinase domain33.  
ICAM-1, a member of the immunoglobulin superfamily of genes that play key 
roles in the binding of leukocytes to the vascular endothelium, is also involved in growth 
and metastasis of cancer. TNF- stimulation of NCI-H838 cells (those used in the 
current study) for 16 hours increased ICAM-1 expression12. Elevated expression of 
ICAM-1 could be linked to a more aggressive tumor phenotype34,35 and to enhanced 
leukocyte infiltration and binding to tumor cells36. Additionally, it was shown that A549 
lung cancer cells overexpressing ICAM-1 exhibited enhanced in vitro cell migration and 
in vivo metastasis, an effect that could be inhibited by an anti-ICAM-1 antibody35. 
This study focused on the phosphorylation of ICAM-1, which is necessary for 
rapid TNF--induced clustering of ICAM-1 resulting in enhanced neutrophil binding15. 
The fact that ropivacaine and lidocaine inhibited this phosphorylation might be beneficial 
in the setting of metastasis. They might also attenuate the binding of circulating cancer 
cells to the vascular endothelium and therefore reduce transmigration and metastasis.  
The well-established cytotoxic effect of local anesthetics, e.g. on neuronal cells37, 
is not considered in the interpretation of our results. The concentrations of ropivacaine, 
lidocaine and chloroprocaine used in this study showed that they did not induce 
cytotoxic effects after 4 hours of treatment. Additionally, an alteration in TNF--induced 
cytotoxicity in our lung cancer cell line was not observed.  
Another finding was the inhibition of tumor cell migration by ropivacaine and 
lidocaine at 1 M. Src is known to play a key role in cell migration, which is necessary 
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for cancer cells to metastasize18. It regulates cytoskeletal changes required for cell 
migration by phosphorylating proteins associated with focal adhesions and actin 
bundling which control cell membrane protrusions38,39. Src is also an upstream regulator 
of Rho family GTPases such as Rac and Rho which together regulate dynamic changes 
in the cytoskeleton and control the disassembly of actin-based cytoskeletal structures 
and cell-matrix adhesions17. We therefore hypothesize that the inhibition of tumor cell 
migration by amide local anesthetics is due to the inhibition of Src. The fact that the 
observed effect of inhibition of migration could be abolished by washout of the local 
anesthetic after 15 minutes (as shown for ropivacaine) also indicates first that the 
observed effect is not due to a cytotoxic effect of the local anesthetic and second, that 
this effect is reversible.  
It is well known that hematogenous dissemination of cancer cells occurs during 
the surgical resection of a tumor40. Circulating tumor cells, detected in the blood 24 
hours post-operatively, are an independent prognostic marker for cancer recurrence 
because of the ability of these cells to extravasate and metastasize41. In accordance 
with the results of our study, we suggest that the perioperative administration of local 
anesthetics may have the potential added benefit of attenuating extravasation and 
metastasis of circulating tumor cells prior to initiation of systemic treatment with 
cytotoxic agents. 
Thus far, the potential beneficial effect of regional anesthesia to improve long-
term outcome after cancer surgery has been attributed to inhibition of the surgical stress 
response and to the decrease in opioid requirements. It has been shown, that opioids 
even at clinically useful concentrations might promote migration and proliferation of 
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tumor cells, e. g. in breast cancer42,43. This work reveals to the best of our knowledge a 
possible mechanism by which local anesthetics might be beneficial in patients with 
cancer and/or undergoing cancer surgery and that this mechanism may be due, at least 
in part, to inhibition of Src tyrosine kinase, a key enzyme in cancer growth and 
metastasis. Future studies will focus on establishing the molecular mechanism of Src 
inhibition and the influence of this inhibition on ICAM-1 phosphorylation and function 
with comparison to established Src inhibitors. 
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 Figure 1. Effect of ropivacaine on the phosphorylation status of Src in NCI-
H838 lung cancer cells 
(A.) (i.) Representative Western blot of NCI-H838 cell Src, phosphorylated at 
tyrosine 419 (pY419 Src, row 1) and total Src (row 2) after treatment with either 
TNF- (20 ng/ml) or with different concentrations of ropivacaine (1 nm, 1 μM, 10 
μM, 100 μM) for 20 minutes. (ii.) Representative blot of NCI-H838 lung cancer 
cell pY419 Src (row 1) and total Src (row 2) after treatment with TNF- (20 ng/ml) 
with or without different concentrations of ropivacaine (1 nm, 1 μM, 10 μM, 100 
μM) for 20 minutes. (B.) Relative density of the Western blot bands of pY419 Src 
normalized to the densitometry values of total Src compared to control (=1.0, 
dashed line) in the absence of TNF- expressed. Data from 3 independent 
experiments shown as scatter plot (n=3). Horizontal line indicates mean for each 
group; * p<0.05 vs. control. (C.) Relative density of the Western blot bands of 
pY419 Src normalized to the densitometry values of total Src after co-incubation 
of ropivacaine with TNF- (20 ng/ml) compared to TNF-α alone (=1.0, dashed 
line). Data from 3 independent experiments shown as scatter plot (n=3). 
Horizontal line indicates mean for each group; * p<0.05 vs. TNF-α, ** p<0.01 vs. 
TNF-α. TNF-α = Tumor necrosis factor-α. 
 
 
Figure 2. Effect of ropivacaine on the phosphorylation status of ICAM-1 in 
NCI-H838 lung cancer cells 
Figure Legends
(A.) (i.) Representative Western blot of NCI-H838 lung cancer cell ICAM-1, 
phosphorylated at tyrosine 512 (pY512 ICAM-1, row 1) and total ICAM-1 (row 2) 
after treatment with either TNF- (20 ng/ml) or different concentrations of 
ropivacaine (1 nm, 1 μM, 10 μM, 100 μM) for 20 minutes. (ii.) Representative blot 
of NCI-H838 cell pY512 ICAM-1 (row 1) and total ICAM-1 (row 2) after treatment 
with TNF- (20 ng/ml) in the presence or absence of different concentrations of 
ropivacaine (1 nm, 1 μM, 10 μM, 100 μM) for 20 minutes. (B.) Relative density of 
the Western blot bands of pY512 ICAM-1 normalized to the densitometry values 
of total ICAM-1 compared to control (=1.0, dashed line) in the absence of TNF-. 
Data from 3 independent experiments shown as scatter plot (n=3). Horizontal line 
indicates mean for each group. (C.) Relative density of the Western blot bands of 
pY512 ICAM-1 normalized to the densitometry values of total ICAM-1 after co-
incubation of ropivacaine with TNF- (20 ng/ml) compared to TNF-α alone (=1.0, 
dashed line). Data from 5 independent experiments shown as scatter plot (n=5). 
Horizontal line indicates mean for each group; * p<0.05 vs. TNF-, ** p<0.01 vs. 
TNF-. TNF-α = Tumor necrosis factor-α. 
 
Figure 3. Effect of lidocaine on the phosphorylation status of Src in NCI-
H838 lung cancer cells 
(A.) (i.) Representative Western blot of NCI-H838 cell Src, phosphorylated at 
tyrosine 419 (pY419 Src, row 1) and total Src (row 2) after treatment with either 
TNF- (20 ng/ml) or with different concentrations of lidocaine (1 nm, 1 μM, 10 
μM, 100 μM) for 20 minutes. (ii.) Representative blot of NCI-H838 lung cancer 
cell pY419 Src (row 1) and total Src (row 2) after treatment with TNF- (20 ng/ml) 
with or without different concentrations of lidocaine (1 nm, 1 μM, 10 μM, 100 μM) 
for 20 minutes. (B.) Relative density of the Western blot bands of pY419 Src 
normalized to the densitometry values of total Src compared to control (=1.0, 
dashed line) in the absence of TNF-. Data from 3 independent experiments 
shown as scatter plot (n=3). Horizontal line indicates mean for each group. (C.) 
Relative density of the Western blot bands of pY419 Src normalized to the 
densitometry values of total Src after co-incubation of lidocaine with TNF- (20 
ng/ml) compared to TNF- alone (=1.0, dashed line). Data from 3 independent 
experiments shown as scatter plot (n=3). Horizontal line indicates mean for each 
group; * p<0.05 vs. TNF-. TNF-α = Tumor necrosis factor-α. 
 
Figure 4. Effect of lidocaine on the phosphorylation status of ICAM-1 in 
NCI-H838 lung cancer cells 
(A.) (i.) Representative Western blot of NCI-H838 lung cancer cell ICAM-1, 
phosphorylated at tyrosine 512 (pY512 ICAM-1, row 1) and total ICAM-1 (row 2) 
after treatment with either TNF- (20 ng/ml) or different concentrations of 
lidocaine (1 nm, 1 μM, 10 μM, 100 μM) for 20 minutes. (ii.) Representative blot of 
NCI-H838 cell pY512 ICAM-1 (row 1) and total ICAM-1 (row 2) after treatment 
with TNF- (20 ng/ml) in the presence or absence of different concentrations of 
lidocaine (1 nm, 1 μM, 10 μM, 100 μM) for 20 minutes. (B.) Relative density of 
the Western blot bands of pY512 ICAM-1 normalized to the densitometry values 
of total ICAM-1 compared to control (=1.0, dashed line) in the absence of TNF-. 
Data from 3 independent experiments shown as scatter plot (n=3). Horizontal line 
indicates mean for each group. (C.) Relative density of the Western blot bands of 
pY512 ICAM-1 normalized to the densitometry values of total ICAM-1 after co-
incubation of lidocaine with TNF- (20 ng/ml) compared to TNF- alone (=1.0, 
dashed line). Data from 3 independent experiments shown as scatter plot (n=3). 
Horizontal line indicates mean for each group; ** p<0.01 vs. TNF-. TNF-α = 
Tumor necrosis factor-α. 
 
Figure 5. Effect of chloroprocaine on the phosphorylation status of Src in 
NCI-H838 lung cancer cells 
(A.) (i.) Representative Western blot of NCI-H838 cell Src, phosphorylated at 
tyrosine 419 (pY419 Src, row 1) and total Src (row 2) after treatment with either 
TNF- (20 ng/ml) or with different concentrations of chloroprocaine (1 nm, 1 μM, 
10 μM, 100 μM) for 20 minutes. (ii.) Representative blot of NCI-H838 lung cancer 
cell pY419 Src (row 1) and total Src (row 2) after treatment with TNF- (20 ng/ml) 
with or without different concentrations of chloroprocaine (1 nm, 1 μM, 10 μM, 
100 μM) for 20 minutes. (B.) Relative density of the Western blot bands of pY419 
Src normalized to the densitometry values of total Src compared to control (=1.0, 
dashed line) in the absence of TNF-. Data from 3 independent experiments 
shown as scatter plot (n=3). Horizontal line indicates mean for each group. (C.) 
Relative density of the Western blot bands of pY419 Src normalized to the 
densitometry values of total Src after co-incubation of chloroprocaine with TNF- 
(20 ng/ml) compared to TNF- alone (=1.0, dashed line). Data from 3 
independent experiments shown as scatter plot (n=3). Horizontal line indicates 
mean for each group. TNF-α = Tumor necrosis factor-α. 
 
Figure 6. Effect of chloroprocaine on the phosphorylation status of ICAM-1 
in NCI-H838 lung cancer cells 
(A.) (i.) Representative Western blot of NCI-H838 lung cancer cell ICAM-1, 
phosphorylated at tyrosine 512 (pY512 ICAM-1, row 1) and total ICAM-1 (row 2) 
after treatment with either TNF- (20 ng/ml) or different concentrations of 
chloroprocaine (1 nm, 1 μM, 10 μM, 100 μM) for 20 minutes. (ii.) Representative 
blot of NCI-H838 cell pY512 ICAM-1 (row 1) and total ICAM-1 (row 2) after 
treatment with TNF- (20 ng/ml) in the presence or absence of different 
concentrations of chloroprocaine (1 nm, 1 μM, 10 μM, 100 μM) for 20 minutes. 
(B.) Relative density of the Western blot bands of pY512 ICAM-1 normalized to 
the densitometry values of total ICAM-1 compared to control (=1.0, dashed line) 
in the absence of TNF-. Data from 3 independent experiments shown as scatter 
plot (n=3). Horizontal line indicates mean for each group. (C.) Relative density of 
the Western blot bands of pY512 ICAM-1 normalized to the densitometry values 
of total ICAM-1 after co-incubation of lidocaine with TNF- (20 ng/ml) compared 
to TNF- alone (=1.0, dashed line). Data from 3 independent experiments shown 
as scatter plot (n=3). Horizontal line indicates mean for each group. TNF-α = 
Tumor necrosis factor-α. 
 
Figure 7. Effect of a sodium channel activator and blocker on the 
phosphorylation status of Src and ICAM-1 in NCI-H838 lung cancer cells 
 (A.) (i.) Representative Western blot of NCI-H838 cell Src, phosphorylated at 
tyrosine 419 (pY419 Src, row 1) and total Src (row 2) after treatment with 
Veratridine (0.015 mM) for 45 minutes. (ii.) Representative blot of NCI-H838 lung 
cancer cell pY512 ICAM-1 (row 1) and total Src (row 2) after treatment with 
Veratridine (0.015 mM) for 45 minutes. (iii.) Relative density of the Western blot 
bands of pY419 Src normalized to total Src (squares) and pY512 ICAM-1 
normalized to total ICAM-1 (circles) compared to control (=1.0, dashed line) after 
treatment with Veratridine (0.015 mM) for 45 minutes. Data from 4 independent 
experiments shown as scatter plot (n=4). Horizontal line indicates mean for each 
group. (B.) (i.) Representative Western blot of NCI-H838 cell Src, phosphorylated 
at tyrosine 419 (pY419 Src, row 1) and total Src (row 2) after pre-treatment with 
tetrodotoxin (TTX, 100 nM) for 10 minutes and subsequent addition of TNF- (20 
ng/ml) for 20 minutes. (ii.) Representative Western blot of NCI-H838 cell ICAM-1, 
phosphorylated at tyrosine 512 (pY512 ICAM-1, row 1) and total ICAM-1 (row 2) 
after pre-treatment with TTX (100 nM) for 10 minutes and subsequent addition of 
TNF- (20 ng/ml) for 20 minutes. (iii.) Relative density of the Western blot bands 
of pY419 Src normalized to the densitometry values of total Src compared to 
control (=1.0, dashed line) after pre-treatment with tetrodotoxin (TTX, 100 nM) for 
10 minutes and subsequent addition of TNF- (20 ng/ml) for 20 minutes. Data 
from 4 independent experiments shown as scatter plot (n=4). Horizontal line 
indicates mean for each group. (iv.) Relative density of the Western blot bands of 
pY512 ICAM-1 normalized to the densitometry values of total ICAM-1 after after 
pre-treatment with tetrodotoxin (TTX, 100 nM) for 10 minutes and subsequent 
addition of TNF- (20 ng/ml) for 20 minutes compared to control (=1.0, dashed 
line). Data from 3 independent experiments shown as scatter plot (n=3). 
Horizontal line indicates mean for each group. TNF-α = Tumor necrosis factor-α. 
 
Figure 8. Migratory ability of NCI-H838 lung cancer cells in the presence of 
ropivacaine, lidocaine and chloroprocaine 
Determination of in vitro transmigration of NCI-H838 cells through a 
polycarbonate membrane after 4 hours in the absence or presence of different 
concentrations (1 pm, 1 nM, 1 μM, 10 μM, 100 μM) of (A.) ropivacaine, (B.) 
lidocaine and (C.) chloroprocaine. (D.) Determination of in vitro transmigration of 
NCI-H838 cells through a polycarbonate membrane after 4 hours in the absence 
or presence of different concentrations (1 pm, 1 nM, 1 μM, 10 μM, 100 μM) of 
ropivacaine for only 15 minutes followed by a wash of the cells with fresh 
medium right before the start of the assay. Cells were stained with a fluorescent 
dye before the start of the assay and lysed after migration through the 
membrane. Fluorescence was measured at 435/535 nm (excitation/emission). 
Values for untreated cells have been set as 1.0 (dashed line). Data from 4 (A. 
and B.) or 3 (C. and D.) independent experiments shown as scatter plot. 
Horizontal line indicates mean for each group; ** p<0.01 vs. control, RFU = 
relative fluorescence units.  
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Supplemental digital content 1: Effect of ropivacaine, lidocaine and 
chloroprocaine on cytotoxicity 
Determination of cytotoxicity of different concentrations (1 nM, 1 μM, 10 μM, 100 μM) 
of ropivacaine (A.), lidocaine (B.) and chloroprocaine (C.) in absence or presence of 
TNF- (20 ng/ml) after 4 hours of treatment. Release of lactate dehydrogenase 
(LDH) was detected as a measure of percent of cytotoxicity. Values shown as scatter 
plot of 3 independent experiments (n=3). Horizontal line indicates mean of each 
group. 
Supplemental Digital Content 1
Click here to download Supplemental Digital Content: Supplemental Digital Content 1.doc 
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Supplemental digital content 2. Effect of TNF- and lipopolysaccharide on the 
phosphorylation status of Src and ICAM-1 in NCI-H838 lung cancer cells. 
Comparison of densitometry values for pY419 Src (squares) and pY512 ICAM-1 
(circles) in the presence of TNF- (20 ng/ml, black squares and circles) or 
lipopolysaccharide (4 g/ml, white squares and circles) compared to untreated cells 
(=1.0, dashed line). Each symbol represents the measure of a single experiment, 
horizontal line represents mean for each group. * p=0.001 vs. control.  
LPS = lipopolysaccharide 
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 Supplemental Digital Content 3. Effect of ropivacaine on the phosphorylation 
status of Src in NCI-H838 lung cancer cells after 4 hours of lipopolysaccharide 
treatment 
 (A.) (i.) Representative Western blot of NCI-H838 cell Src, phosphorylated at tyrosine 
419 (pY419 Src, row 1) and total Src (row 2) after treatment either with bacterial 
lipopolysaccharide (4 μg/ml) or with different concentrations of ropivacaine (1 nm, 1 μM, 
10 μM, 100 μM) for 4 hours. (ii.) Representative blot of NCI-H838 lung cancer cell 
pY419 Src (row 1) and total Src (row 2) after treatment either with lipopolysaccharide (4 
μg/ml) or without different concentrations of ropivacaine (1 nm, 1 μM, 10 μM, 100 μM) for 
4 hours. (B.) Relative density of the Western blot bands of pY419 Src normalized to the 
densitometry values of total Src compared to control (=1.0, dashed line) in the absence 
of lipopolysaccharide. Data from 3 independent experiments shown as scatter plot (n=3). 
Horizontal line indicates mean for each group; * p<0.05 vs. control, ** p<0.01 vs. control. 
(C.) Relative density of the Western blot bands of pY419 Src normalized to the 
densitometry values of total Src after co-incubation of ropivacaine with 
lipopolysaccharide (20 ng/ml) compared to lipopolysaccharide alone (=1.0, dashed line). 
Data from 3 independent experiments shown as scatter plot (n=3). Horizontal line 
indicates mean for each group; ** p<0.01 vs. lipopolysaccharide.      
LPS = lipopolysaccharide 
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 Supplemental Digital Content 4. Effect of ropivacaine on the phosphorylation 
status of ICAM-1 in NCI-H838 lung cancer cells after 4 hours of lipopolysaccharide 
treatment 
 (A) (i.) Representative Western blot of NCI-H838 lung cancer cell ICAM-1, 
phosphorylated at tyrosine 512 (pY512 ICAM-1, row 1) and total ICAM-1 (row 2) after 
treatment with either lipopolysaccharide (4 μg/ml) or different concentrations of 
ropivacaine (1 nm, 1 μM, 10 μM, 100 μM) for 4 hours. (ii.) Representative blot of NCI-
H838 cell pY512 ICAM-1 (row 1) and total ICAM-1 (row 2) after treatment with either 
lipopolysaccharide (4 μg/ml) in the presence or absence of different concentrations of 
ropivacaine (1 nm, 1 μM, 10 μM, 100 μM) for 4 hours. (B.) Relative density of the 
Western blot bands of pY512 ICAM-1 normalized to the densitometry values of total 
ICAM-1 compared to control (=1.0, dashed line) in the absence of lipopolysaccharide. 
Data from 3 independent experiments shown as scatter plot (n=3). Horizontal line 
indicates mean for each group. (C.) Relative density of the Western blot bands of pY512 
ICAM-1 normalized to the densitometry values of total ICAM-1 after co-incubation of 
ropivacaine with lipopolysaccharide (4 µg/ml) compared to lipopolysaccharide alone 
(=1.0, dashed line). Data from 3 independent experiments shown as scatter plot (n=3). 
Horizontal line indicates mean for each group; ** p<0.01 vs. lipopolysaccharide.  
LPS = lipopolysaccharide. 
 
